BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17020781)

  • 1. Effects of higenamine and its 1-naphthyl analogs, YS-49 and YS-51, on platelet TXA2 synthesis and aggregation.
    Pyo MK; Kim JM; Jin JL; Chang KC; Lee DH; Yun-Choi HS
    Thromb Res; 2007; 120(1):81-6. PubMed ID: 17020781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
    Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism for antiplatelet effect of onion: AA release inhibition, thromboxane A(2)synthase inhibition and TXA(2)/PGH(2)receptor blockade.
    Moon CH; Jung YS; Kim MH; Lee SH; Baik EJ; Park SW
    Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):277-83. PubMed ID: 10883058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic effects of YS-49 and YS-51--1-naphthylmethyl analogs of higenamine.
    Yun-Choi HS; Pyo MK; Park KM; Chang KC; Lee DH
    Thromb Res; 2001 Nov; 104(4):249-55. PubMed ID: 11728526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization.
    Jin YR; Cho MR; Ryu CK; Chung JH; Yuk DY; Hong JT; Lee KS; Lee JJ; Lee MY; Lim Y; Yun YP
    J Pharmacol Exp Ther; 2005 Jan; 312(1):214-9. PubMed ID: 15328379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I4, a new synthetic sulfonylurea compound, inhibits the action of TXA2 in vivo and in vitro on platelets and aorta vascular smooth muscle.
    Lu N; Zhan M; Gao C; Wu G; Zhang H
    Thromb Res; 2012 Oct; 130(4):e209-15. PubMed ID: 22909828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-thrombotic effects of higenamine.
    Yun-Choi HS; Pyo MK; Park KM; Chang KC; Lee DH
    Planta Med; 2001 Oct; 67(7):619-22. PubMed ID: 11582538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations.
    Buccellati C; Sala A; Rossoni G; Capra V; Rovati GE; Di Gennaro A; Folco G; Colli S; Casagrande C
    J Pharmacol Exp Ther; 2006 May; 317(2):830-7. PubMed ID: 16399881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of the Korean herbal medicine, Dae-Jo-Whan, on platelet-activating factor-induced platelet aggregation.
    Chang GT; Kang SK; Kim JH; Chung KH; Chang YC; Kim CH
    J Ethnopharmacol; 2005 Dec; 102(3):430-9. PubMed ID: 16125889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of release and role of adenosine diphosphate and thromboxane A2 during collagen-induced aggregation of platelets from cattle with Chediak-Higashi syndrome.
    Honda N; Ohnishi K; Fujishiro T; Ikeda M; Ito K
    Am J Vet Res; 2007 Dec; 68(12):1399-406. PubMed ID: 18052747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
    Block HU; Förster W; Heinroth I
    Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of oxidative-stress-induced platelet aggregation by androgen at physiological levels via its receptor is associated with the reduction of thromboxane A2 release from platelets.
    Li S; Li X; Li J; Deng X; Li Y
    Steroids; 2007 Nov; 72(13):875-80. PubMed ID: 17825336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats].
    Xu HL; Feng YP
    Yao Xue Xue Bao; 2001 May; 36(5):329-33. PubMed ID: 12584852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of U46619 induced human platelet aggregation by aspirin.
    Kim JM; Koo YK; Jin J; Lee YY; Park S; Yun-Choi HS
    Platelets; 2009 Mar; 20(2):111-9. PubMed ID: 19235053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity.
    Jin YR; Im JH; Park ES; Cho MR; Han XH; Lee JJ; Lim Y; Kim TJ; Yun YP
    J Cardiovasc Pharmacol; 2008 Jan; 51(1):45-54. PubMed ID: 18209568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantioselective synthesis of (R)-(+)- and (S)-(-)-higenamine and their analogues with effects on platelet aggregation and experimental animal model of disseminated intravascular coagulation.
    Pyo MK; Lee DH; Kim DH; Lee JH; Moon JC; Chang KC; Yun-Choi HS
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4110-4. PubMed ID: 18556200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity.
    Fuse I; Hattori A; Mito M; Higuchi W; Yahata K; Shibata A; Aizawa Y
    Thromb Haemost; 1996 Dec; 76(6):1080-5. PubMed ID: 8972034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effect of NQ12: a possible mechanism through the arachidonic acid cascade.
    Jin YR; Han XH; Lee JJ; Lim Y; Kim TJ; Yoo HS; Hong JT; Lee CK; Yun YP
    J Pharmacol Sci; 2007 Oct; 105(2):193-200. PubMed ID: 17951980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.